|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2017. CA Cancer J Clin. 67:7–30. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Scher HI, Halabi S, Tannock I, Morris M,
Sternberg CN, Carducci MA, Eisenberger MA, Higano C, Bubley GJ,
Dreicer R, et al: Design and end points of clinical trials for
patients with progressive prostate cancer and castrate levels of
testosterone: Recommendations of the prostate cancer clinical
trials working group. J Clin Oncol. 26:1148–1159. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Li P, Yang R and Gao WQ: Contributions of
epithelial-mesenchymal transition and cancer stem cells to the
development of castration resistance of prostate cancer. Mol
Cancer. 13:552014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Sun Y, Wang BE, Leong KG, Yue P, Li L,
Jhunjhunwala S, Chen D, Seo K, Modrusan Z, Gao WQ, et al: Androgen
deprivation causes epithelial-mesenchymal transition in the
prostate: Implications for androgen-deprivation therapy. Cancer
Res. 72:527–536. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Maeda M, Johnson KR and Wheelock MJ:
Cadherin switching: Essential for behavioral but not morphological
changes during an epithelium-to-mesenchyme transition. J Cell Sci.
118:873–887. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Zeisberg M and Neilson EG: Biomarkers for
epithelial-mesenchymal transitions. J Clin Invest. 119:1429–1437.
2009. View
Article : Google Scholar : PubMed/NCBI
|
|
7
|
Peinado H, Quintanilla M and Cano A:
Transforming growth factor beta-1 induces snail transcription
factor in epithelial cell lines: Mechanisms for epithelial
mesenchymal transitions. J Biol Chem. 278:21113–21123. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Graham TR, Zhau HE, Odero-Marah VA,
Osunkoya AO, Kimbro KS, Tighiouart M, Liu T, Simons JW and O'Regan
RM: Insulin-like growth factor-I-dependent up-regulation of ZEB1
drives epithelial-to-mesenchymal transition in human prostate
cancer cells. Cancer Res. 68:2479–2488. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Kwok WK, Ling MT, Lee TW, Lau TC, Zhou C,
Zhang X, Chua CW, Chan KW, Chan FL, Glackin C, et al: Up-regulation
of TWIST in prostate cancer and its implication as a therapeutic
target. Cancer Res. 65:5153–5162. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Qin Q, Xu Y, He T, Qin C and Xu J: Normal
and disease-related biological functions of Twist1 and underlying
molecular mechanisms. Cell Res. 22:90–106. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Zhu ML and Kyprianou N: Role of androgens
and the androgen receptor in epithelial-mesenchymal transition and
invasion of prostate cancer cells. FASEB J. 24:769–777. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Miao L, Yang L, Li R, Rodrigues DN, Crespo
M, Hsieh JT, Tilley WD, de Bono J, Selth LA and Raj GV: Disrupting
androgen receptor signaling induces snail-mediated
epithelial-mesenchymal plasticity in prostate cancer. Cancer Res.
77:3101–3112. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Wu K, Gore C, Yang L, Fazli L, Gleave M,
Pong RC, Xiao G, Zhang L, Yun EJ, Tseng SF, et al: Slug, a unique
androgen-regulated transcription factor, coordinates androgen
receptor to facilitate castration resistance in prostate cancer.
Mol Endocrinol. 26:1496–1507. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Shiota M, Itsumi M, Takeuchi A, Imada K,
Yokomizo A, Kuruma H, Inokuchi J, Tatsugami K, Uchiumi T, Oda Y and
Naito S: Crosstalk between epithelial-mesenchymal transition and
castration resistance mediated by Twist1/AR signaling in prostate
cancer. Endocr Relat Cancer. 22:889–900. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Feng S, Dakhova O, Creighton CJ and
Ittmann M: Endocrine fibroblast growth factor FGF19 promotes
prostate cancer progression. Cancer Res. 73:2551–2562. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Acevedo VD, Gangula RD, Freeman KW, Li R,
Zhang Y, Wang F, Ayala GE, Peterson LE, Ittmann M and Spencer DM:
Inducible FGFR-1 activation leads to irreversible prostate
adenocarcinoma and an epithelial-to-mesenchymal transition. Cancer
Cell. 12:559–571. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Sugiyama N, Varjosalo M, Meller P, Lohi J,
Hyytiäinen M, Kilpinen S, Kallioniemi O, Ingvarsen S, Engelholm LH,
Taipale J, et al: Fibroblast growth factor receptor 4 regulates
tumor invasion by coupling fibroblast growth factor signaling to
extracellular matrix degradation. Cancer Res. 70:7851–7861. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Huang X, Yang C, Jin C, Luo Y, Wang F and
McKeehan WL: Resident hepatocyte fibroblast growth factor receptor
4 limits hepatocarcinogenesis. Mol Carcinog. 48:553–562. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Ricol D, Cappellen D, El Marjou A,
Gil-Diez-de-Medina S, Girault JM, Yoshida T, Ferry G, Tucker G,
Poupon MF, Chopin D, et al: Tumour suppressive properties of
fibroblast growth factor receptor 2-IIIb in human bladder cancer.
Oncogene. 18:7234–7243. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Yan G, Fukabori Y, McBride G,
Nikolaropolous S and McKeehan WL: Exon switching and activation of
stromal and embryonic fibroblast growth factor (FGF)-FGF receptor
genes in prostate epithelial cells accompany stromal independence
and malignancy. Mol Cell Biol. 13:4513–4522. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Kurosu H and Kuro OM: The Klotho gene
family as a regulator of endocrine fibroblast growth factors. Mol
Cell Endocrinol. 299:72–78. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Fu L, John LM, Adams SH, Yu XX, Tomlinson
E, Renz M, Williams PM, Soriano R, Corpuz R, Moffat B, et al:
Fibroblast growth factor 19 increases metabolic rate and reverses
dietary and leptin-deficient diabetes. Endocrinology.
145:2594–2603. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Choi M, Moschetta A, Bookout AL, Peng L,
Umetani M, Holmstrom SR, Suino-Powell K, Xu HE, Richardson JA,
Gerard RD, et al: Identification of a hormonal basis for
gallbladder filling. Nat Med. 12:1253–1255. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Ye X, Guo Y, Zhang Q, Chen W, Hua X, Liu
W, Yang Y and Chen G: βKlotho suppresses tumor growth in
hepatocellular carcinoma by regulating Akt/GSK-3β/cyclin D1
signaling pathway. PloS One. 8:e556152013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Liu Z, Qi S, Zhao X, Li M, Ding S, Lu J
and Zhang G: Metformin inhibits 17β-estradiol-induced
epithelial-to-mesenchymal transition via βKlotho-related ERK1/2
signaling and AMPKα signaling in endometrial adenocarcinoma cells.
Oncotarget. 7:21315–21331. 2016.PubMed/NCBI
|
|
26
|
Poh W, Wong W, Ong H, Aung MO, Lim SG,
Chua BT and Ho HK: Klotho-beta overexpression as a novel target for
suppressing proliferation and fibroblast growth factor receptor-4
signaling in hepatocellular carcinoma. Mol Cancer. 11:142012.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Robinson D, Van Allen EM, Wu YM, Schultz
N, Lonigro RJ, Mosquera JM, Montgomery B, Taplin ME, Pritchard CC,
Attard G, et al: Integrative clinical genomics of advanced prostate
cancer. Cell. 161:1215–1228. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Liao RS, Ma S, Miao L, Li R, Yin Y and Raj
GV: Androgen receptor-mediated non-genomic regulation of prostate
cancer cell proliferation. Transl Androl Urol. 2:187–196.
2013.PubMed/NCBI
|
|
29
|
Virtakoivu R, Mai A, Mattila E, De
Franceschi N, Imanishi SY, Corthals G, Kaukonen R, Saari M, Cheng
F, Torvaldson E, et al: Vimentin-ERK signaling uncouples Slug gene
regulatory function. Cancer Res. 75:2349–2362. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Ichikawa K, Kubota Y, Nakamura T, Weng JS,
Tomida T, Saito H and Takekawa M: MCRIP1, an ERK substrate,
mediates ERK-induced gene silencing during epithelial-mesenchymal
transition by regulating the co-repressor CtBP. Mol Cell. 58:35–46.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Nakai K, Yoneda K, Haba R, Kushida Y,
Katsuki N, Moriue J, Moriue T, Koura A, Yokoi I, Ishikawa E, et al:
[beta]Klotho expression is reduced in human non-melanoma skin
cancer. Int J Dermatol. 54:e431–e433. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Luo Y, Yang C, Lu W, Xie R, Jin C, Huang
P, Wang F and McKeehan WL: Metabolic regulator betaKlotho interacts
with fibroblast growth factor receptor 4 (FGFR4) to induce
apoptosis and inhibit tumor cell proliferation. J Biol Chem.
285:30069–30078. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Zhao J, Ou B, Han D, Wang P, Zong Y, Zhu
C, Liu D, Zheng M, Sun J, Feng H and Lu A: Tumor-derived CXCL5
promotes human colorectal cancer metastasis through activation of
the ERK/Elk-1/Snail and AKT/GSK3β/β-catenin pathways. Mol Cancer.
16:702017. View Article : Google Scholar : PubMed/NCBI
|
